Drug intelligence / Profile preview

SPVX04

Development stage: Preclinical
Lead developer: Stablepharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SPVX04 is a preclinical-stage, fridge-free vaccine candidate being developed by Stablepharma for the prevention of tetanus and diphtheria (Td). It is formulated using Stablepharma's proprietary StablevaX™ technology, which reformulates vaccines into a dry, thermostable format stored inside a pre-filled syringe delivery system. This eliminates the need for cold-chain storage and transport, allowing the vaccine to remain stable at room temperature and be reconstituted immediately prior to administration.

Targets

DT/DTD (Diphtheria toxin / diphtheria toxoid antigen epitopes)

Beyond the preview

Go deeper on SPVX04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPVX04.

Explore the full profile